The flagship clinical development asset for Poolbeg is POLB 001, a small molecule p38 MAP kinase inhibitor engineered to address severe inflammatory conditions. In recent clinical disclosures, Poolbeg announced that its clinical trial evaluating POLB 001 in a topical formulation successfully passed a formal …
The primary driver of Futura's commercial trajectory is its international network of licensing and distribution agreements with tier-one pharmaceutical and consumer healthcare leaders. In the United States, Futura secured an exclusive commercialPartnershipwith consumer health giant Haleon plc to market and distribute Eroxon across major …
The flagship commercial diagnostic platform for Genedrive is the Genedrive® MT-RNR1 ID Kit, the world's first point-of-care genetic test designed to prevent antibiotic-induced hearing loss in critically ill infants. When premature infants require emergency gentamicin antibiotic treatment in neonatal intensive care units (NICUs), those …
The primary clinical focus for Genflow is developing GF-1002, a specialized adeno-associated virus (AAV) vector carrying a centenarian variant of the human SIRT6 gene, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Preclinical in-vivo disease models have demonstrated that delivery of the …
The operational engine of GSK's biopharmaceutical growth is its world-leading Vaccines and Specialty Medicines franchises. In Vaccines, blockbuster shinglesVaccineShingrix continues to drive global sales expansion, while Arexvy—the world's first approved respiratory syncytial virus (RSV) vaccine for older adults—has captured leadingMarket Shareacross developed healthcare markets. …
Unlike dedicated operating businesses, Gunsynd operates as an AIM Rule 15Investmentcompany specializing in the natural resources,Miningexploration, and energy transition sectors. The company's investment strategy focuses on acquiring strategic shareholdings and convertibleDebtinstruments in early-stage exploration projects across copper, gold, nickel, and battery metals jurisdictions. By …
The principal focus for HemoGenyx centres on advancing its Phase 1 clinical trial evaluating HEMO-CAR-T in relapsed or refractory AML patients. Following the resolution of earlier regulatory clearances with the United States Food and Drug Administration (FDA), the clinical trial is designed to evaluate …
The primary growth engine for Hikma (LSE:HIK) is its market-leading US Injectables franchise, which supplies hospitals, surgery centres, and emergency clinics with vital sterile liquid medications, pain management agents, and cardiovascular therapies. To sustain competitive differentiation against generic price erosion, Hikma has continuously invested …
A primary engine of Haleon's organic revenue trajectory is its market-leading Oral Health division, where Sensodyne and Parodontax continue to captureMarket Shareacross developed and emerging economies. Haleon has combined brand value, continuous scientific product reformulations, and clinical dentist endorsements to maintain positive volume mix …
To improve operating profit margins and establish closer clinical relationships with hospital decision-makers, Inspiration Healthcare (LSE:IHC) has strategically restructured its commercial go-to-market channels. In core domestic territories, such as the United Kingdom and Ireland, the company operates a direct clinical sales and service model. …